Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes
NCT07521631 on ClinicalTrials.gov · last registry update 2026-04-13
An unusually large phase 2: 372 participants, more than double the 114 typical for the stage. Due to report 4 February 2027, alongside 30 other tracked readouts that quarter. Primary outcome, as filed: Primary Outcome. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P2
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 372
- Started
- 2026-03-31
- Primary completion
- 2027-02-04 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Primary Outcome
Conditions studied
Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.